CUMULATIVE INDEX 1999

Volume 29

January  THE ROCKet SCIENCE OF CANINE UROLITHIASIS, pages 1–306
March  PROGRESS IN GASTROENTEROLOGY, pages 307–610
May  CLINICAL ANESTHESIA, pages 611–836
July  PEDIATRIC: PUPPIES AND KITTENS, pages 837–1028
September  FRACTURE MANAGEMENT AND BONE HEALING, pages 1029–1282
November  DERMATOLOGY, pages 1283–1496

Note: Page numbers of article titles are in boldface type

Abscess, orbital, 1006–1007
pancreatic, in cat, 568
Absorptiometry, dual energy X-ray, 1258
Absorption, by small intestine, tests of, 447–453
Acepromazine, 704
Acetabulum, screws and bone plates to reconstruct, 1120
Acetohydroxamic acid, to treat struvite uroliths, 92
Acne, canine, 909
Acral mutilation syndrome, 909–910
Acrodermatitis, lethal, 916
Acrylic pin splints, 1138–1139
Adenosine kinase antagonism, 732
Adrenal disease, early spay-neuter and, 941
Aging, anesthetic considerations in, 688–697
effects of, on pharmacokinetics of propofol, 750–751, 751
physiological changes associated with, 683–687
Airway, establishment of, in cardiopulmonary resuscitation, 962
diseases of, in young cats, 949
patency of, cardiopulmonary resuscitation and, 819–820
upper, diseases of, in young cats, 946–949
"Alabama Rot," 1331
Alfentanil, 729
Alignment pin, 1181–1182
Allergens, arachnid, 1385–1386
insect, 1385–1386
Allergic inhalant dermatitis, 910
Allergy, food, as response to dietary antigen, 491
Allergy testing, in atopy, 1440–1442
Allopurinol-induced xanthine uroliths. See Xanthine uroliths, allopurinol-induced.
Alopecia, in rabies vaccine-induced vasculitis, 1330–1331
Alpha2 adrenoceptors, 737–738
Alpha2 agents, 731
Alpha2 agonists, 704–705
and antagonists, 737–745
physiological effects of, 738–739
Alpha2 antagonists, 742–743
Aminoglycosides, in canine parvovirus type 2 enteritis, 980
Amitraz, in canine demodicosis, 1426–1427
extra-label protocols for, 1427–1428
Ammonium acid urate uroliths, canine, medical dissolution of, 188–189
Ammonium urate nephroliths, canine, 233
Amphotericin B, 1455
Amphotericin B lipid complex, 1454–1455
Ampicillin, crystalluria associated with, 263
Analgesia, versus tranquilization, 702
Analgesics, 705–714
and anesthetics, doses of, for epidural administration, 711

1475
Anticholinergics (Continued)
and local anesthetics, techniques of, 709–713
and pain, 701–717
commonly employed, 706
constant rate infusion of, 707–708
continuous absorption of, 708–709
delivery systems for, 707–714
monitoring of patients receiving, 714
newer, 719–735
oral administration of, 713–714
scheduled parenteral administration of, 707
Anaphylaxis, in small animals, clinical signs of, 1390
treatment of, 1390
Anemia, severe, in puppies and kittens between 2 and 6 weeks of age, 975
Anesthesia, 611–829
and newer diagnostic and surgical techniques, impact of, 665–682
drug interactions during, 629–643
fluid balance and, 611
for early spay-neuter, 936–937
for voiding urohydropropulsion, 286
imaging studies for, 668–674
inhaletal equipment for, 645–663
outpatient, propofol for, 765–766
Anesthesia machines, 645–647
veterinary, 650–652, 653, 654
Anesthetics, dissociative, for geriatric patient, 694
general, inhalatal, for geriatric patient, 695–697
injectable, for geriatric patient, 693–695
highly protein-bound, 632
interactions involving, 638–640
Angiotensin II, 825–826
Ankylolobpharon, physiological, 1007–1008
Antacids, 360–361
Antibiotic-impregnated polymethyl methacrylate, disadvantages of, 1267
in orthopedic infections, 1264–1266
Antibiotic-responsive enteropathies, 536–537
Antibiotics, beta-lactam, 1453
in mycobacterial dermatitis, 1295–1298
interactions of, 636–637
macrolide, 1453–1454
systemic, in canine parvovirus type 2 enteritis, 980–981
Anticholinergics, 352, 364
for geriatric patient, 689
Antiemetics, 343
centrally acting, 350–352
in canine parvovirus type 2 enteritis, 981–982
peripherally acting, 352
Antidiotoxin, in canine parvovirus type 2 enteritis, 982
Antifungal agents, 1454
Antigen presentation, and regulation of gastrointestinal immune response, 479–481
Antihistamines, nonsedating, for treating atopy, 1449–1451
Antimicrobial therapy, in canine demodiosis, 1433
Antimicrobics, sulfonamide. See Sulfonamides.
Antimuscarinics, 350
Antineoplastic agents, drug interactions with, 637
Antisecretory drugs, 366–367
Antulcer drugs, 353–362
Apids, stinging by, 1388–1389
Arachnid allergens, 1385–1386
Arachnids, and insects, hypersensitivity to. See Insect(s), and arachnid hypersensitivity.
Asthenia, cutaneous, 910–911
Atipamazole, 743
Atopy, 910
age of onset of, 1438
allergy testing in, 1440–1442
breed predilection for, 1438
diagnosis of, 1438–1442
and treatment of, advances in, 1437–1447
drugs for treating, 1449–1451
history taking in, 1438–1439
immunopathogenesis of, 1445
incidence of, 1437
physical examination in, 1439–1440
treatment of, 1442–1445
Atracurium, 813
Atropine, 826
Autoimmune disease, oral tolerance for management of, 492
Autonomic nervous system, aging and, 686–687
Avermectin, for flea control, 1414
Azathioprine, in inflammatory bowel disease, 515
Azithromycin, 1453
Bacterial infections, in kittens, 862
Bacterial overgrowth, small intestinal. See Intestine(s), small, bacterial overgrowth in.
Barbiturates, ultrashort-acting, for geriatric patient, 693–694
Barium-impregnated polyethylene spheres, for assessment of gastrointestinal motility, 312–314, 315
to test intestinal motility, 463, 464
Behavior, early spay-neuter and, 940–941
Benzodiazepines, 704
Bone grafting, biology of, 1208–1209
cancellous, in biological osteosynthesis, 1182–1183
Bone grafts, 1207–1219
autogenous and allogenic cancellous, 1209–1211
compositions of, 1207–1208
definitions associated with, 1207–1208
future directions in, 1216
implant immunogenicity and methods of sterilization, 1214
mechanical support with, 1209
osteocoduction with, 1208–1209
osteogenesis with, 1208
osteoduction with, 1208
types of, 1207
vascularized, 1213
Bone healing, biology of, 1037–1039
bones and, 1029–1044
complications of, radiographic interpretation of, 1252–1257
effects of bone- and nonbone-derived growth factors on, 1221–1246
fracture management and, 1029–1274
fracture union in, 1039
growth factors influencing, 1039–1040
ideal time line for, 1250–1252
in presence of osteomyelitis, 1256–1257
inflammatory phase of, 1037–1038
primary, 1249, 1250
radiographic interpretation of, 1249–1252
remodeling in, 1038–1039
repair phase of, 1038
secondary, 1249–1250, 1251
with external skeletal fixators, 1141–1142
Bone matrix, demineralized, 1213
Bone morphogenic proteins, 1215, 1229–1231
Bone plate-pin construct, 1128–1130
Bone plates, application of, 1124–1127, 1128
gliding screw holes in, 1122, 1123
in fractures, 1077
removal of, 1131–1132
screw holes in, 1121–1122
screws and, fracture fixation with, 1117–1133
shape of, 1119, 1120
sizes of, 1119
surfaces of, 1120–1121
Bone plating, buttress, 1125–1127, 1128
dynamic compression, 1124, 1125, 1126, 1127
neutralization, 1125, 1127
Bordetellosis, feline, 950–951
Botanicals, in flea control, 1407–1409
Bowel disease, inflammatory. See Inflammatory bowel disease
Brachygnathism, mandibular, 889
Brain stem auditory evoked response, 902–905

Bernese Mountain Dog, systemic histiocytosis of, 1319–1321
Beta-lactam antibiotics, 1453
Bile acids, deconjugated, assessment of, to diagnose intestinal bacterial overgrowth, 541–542
Bilious vomiting syndrome, 381
Biodegradable implants, 1130–1131
Bird-tongue, in puppies and kittens, 873–874
Black Rhinoceros, metabolic epidermal necrosis in, clinical presentation of, 1339–1340
Bladder, pancreatic, in cat, 568
Bladder stones, extracorporeal shock-wave lithotripsy in, 300–301
Blood products, newer, fluid therapy and, 611–628
Blood substitutes, adverse effects of, 624
ideal, 622
indications for, 623
special considerations for use of, 623–624
Blood supply, to bone, 1035–1037
Blood transfusions, alternatives to, 622–624
Bone(s), age of, as influence on mechanical behavior of bone, 1056–1057
and bone healing, 1029–1044
basic biomechanics of, 1045–1051
cancellous, and cortical, material properties of, 1052–1054
cortical, and cancellous, material properties of, 1052–1054
effect of loading rates on, 1054–1055
orientation and mode of loading of, 1055
stress-strain curve for, 1048
healing of. See Bone healing.
healing response of, manipulating and enhancing of, 1214–1216
influence of bone geometry on, 1059–1060
influence of disease and bone defects on, 1057–1058
loading of, parallel to surface, 1050
perpendicular to surface, 1049
long, bending of, 1061, 1066–1070
complex or combined loading on, 1071–1072
compressive loading on, 1061, 1062–1064
force and its effect on, 1060–1072
shear loading on, 1065–1066, 1067
tensile loading on, 1061, 1064–1065, 1066
torsional loading of, 1061, 1070–1071
mechanical behavior of, 1051–1060
normal anatomy of, 1029–1035
whole, load-deformation curve for, 1046
Bone cement, biodegradable, in orthopedic infections, 1269–1270
Breath hydrogen test, to diagnose intestinal bacterial overgrowth, 539–541
Breathing, cardiopulmonary resuscitation and, 820–822
spontaneous, establishment of, in cardiopulmonary resuscitation, 962
Breathing systems, 652–657
Butyrophenone derivatives, 350–351
Calcium oxalate nephroliths, canine, 232–233
Calcium oxalate urolithiasis, canine, 123–139
and struvite urolithiasis, recurrence of, minimizing of, 105
case study of, 124–125
preventive therapy in, length of time for, 137–138
therapy in, monitoring response to, 136–137
Calcium oxalate uroliths, canine, and concurrent diseases, 119
and struvite uroliths, changing prevalence of, 24–28
elimination of, options for, 126–127
epidemiology of, 113–122
familial patterns of, 114
formation of, reasons for, 125–126
gender and age factors in, 114–115
prevention of, struvite stone formation during, 138
reciprocal relationship between, 119–120
recurrence of, minimizing of, 127–136
role of diet in, 115–118
Calcium phosphate uroliths, canine, case report of, 152–156
etiopathogenesis of, 144–150
management of, recommendations for, 158–159
medical management of, 150–152
mineral composition of, 142–144
prevalence of, 142
prevention of, 150–152
Canine urolithiasis. See Urolithiasis, canine.
Canines, base narrow, in puppies, 888–889
maxillary, rostroversion of, 888
Carbamates, in flea control, 1409
Carcinoma, squamous cell, of claw bed, in Giant Schnauzers, 1358–1359
Cardiac arrest, drugs for treatment of, 825–827
Cardiac disease, congenital, 998
Cardiac massage, 822–824
active compression-decompression cardiopulmonary resuscitation in, 824
high-impulse external chest compression in, 822–823
interposed abdominal compression in, 823
simultaneous compression and ventilation in, 822
vest cardiopulmonary resuscitation in, 823
Cardiomegaly, 998
Cardiopulmonary resuscitation, and oxygen therapy, 959–969
life support following, 964
lifesaving support procedures in, 962–964
new techniques for, 964–965
new thoughts on, 819–829
open-chest, 964
reasons for, 962
training in, and readiness for, 959–961
Cardiovascular system, changes in, associated with aging, 684
effects of desflurane on, 796–797
effects of etomidate on, 780–781
effects of sevoflurane on, 796–797
effects of Telazol on, 785–786
function of, effects of propofol on, 760–761
Carprofen, 725, 726
Castration. See Spay-neuter, early.
Casts. See also External coaptation.
and splints, to stabilize fractures, 1076
Cat flea, 1407
Cathartics, 369
irritant, 371–372
osmotic, 370–371
Cats, and dogs, diagnostic imaging of gastrointestinal tract of, 307–342
nephrolithiasis in, 231–250
breeds of, carrying white coat pigment gene, 899
constipation in, 592–596
cutaneous tuberculosis in, 1299–1300
exocrine pancreatic disorders in, 551–574
extracorporeal shock-wave lithotripsy for treatment of, 301
facial and nasal dermatitis and stomatitis in, in herpesvirus 1, 1281–1290
idiopathic megacolon in, pathogenesis, diagnosis, and therapy of, 589–603
leprosy in, 1298
metabolic epidermal necrosis in, 1339
Cefpodoxime, 1453
Celiac disease, 488–491
Cellulitis, juvenile, 916, 977
orbital, 1006–1007
Central nervous system, aging and, 686
effects of desflurane on, 798
effects of etomidate on, 780
Effects of sevoflurane on, 798
Cerclage wires, complications of, 1109, 1110
full-cerclage, 1101, 1102, 1104, 1106–1107, 1113, 1114
hemicerclage, 1107
orthopedic wire sizes for, 1106
wire tightening and knot formation using, 1107–1109
Cerebral resuscitation, 827
Cesarean section, propofol for, 766–767
Cetirizine, 1450
Cheiloschisis/palatoschisis, in puppies and kittens, 872
Chromium 51-labelled albumin, to detect
protein-losing enteropathy, 459–460
Circuits, closed and low-flow, for
administration of desflurane and sevoflurane, 801–802
Circular external skeletal fixation. See Skeletal fixation, circular external.
Circular external skeletal fixators, components of, 1162–1163
for distraction osteogenesis, 1188–1189
in fractures, 1078–1079
Circulation, improvement of, in
cardiopulmonary resuscitation, 963
Cisapride, in gastric motility disorders, 387–389
Cisatracurium, 815
Clamp, Secur-U external fixation, 1139, 1140
Clarithromycin, 1453
Claw, canine, anatomy of, 1357–1358
normal, histological features of, 1359
Claw bed, squamous cell carcinoma of, in
Giant Schnauzers, 1358–1359
Claw disease(s), canine, clinical
examination in, 1362–1363
diagnosis and management of, 1357–1371
diagnostic approach to, 1362–1367
diagnostic tests in, 1363–1367
history taking in, 1362
literature review of, 1358–1362
recent prospective study of, 1361
therapy of, systemic, 1368–1370
topical, 1367
Cleft lip/Cleft palate, in puppies and kittens, 872
Clemastine, 1449–1450
Closed containers, as indication chambers, 662
Cobalamin concentrations, serum, assaying of, 449–453
tests of, to diagnose intestinal bacterial
overgrowth, 542–543
Cochlea, cross-section of, 897
Collagen fibers, in bone, 1033, 1034
Collagen implants, in orthopedic
infections, 1270
Colloids, 617–622
natural, 621–622
synthetic, 619–621
Colon, structure of, 577–578
Colonic fluid transport, and electrolyte
transport, in health and disease, 577–588
Colonic prokinetic agents, 598–599
Colonic transport, in disease, 582–585
in health, 579–582
Colonic transport function, regulation of,
581–582
Colonic water transport, 580–581
Computed tomography, anesthesia for,
668–670
to measure bone density, 1258–1259
Conduction deafness, 896
Congenital cardiac disease, 998
Conjunctiva, lacerations of, 1009
Conjunctivitis, 1009
Constipation, in cat, differential diagnosis of, 592, 593
management of, 594
medical therapy of, 596
Contrast agents, radiopaque, crystalluria
associated with, 263–265
Contrast media, intravenous, for computed
tomography, 668–670
Cornea, erosions and ulcerations of, uncomplicated, treatment of,
1010–1011
laceration of, treatment of, 1009–1010
ulcerations of, complicated, treatment of,
1011–1012
Cortical grafts, autografts, allografts, and
alloimplants, 1211–1213
contraindications to, 1211–1212
indications for, 1211
Corticosteroids, in canine parvovirus type
2 enteritis, 982
in inflammatory bowel disease, 513
Corticotomy/osteotomy, in distraction
osteogenesis, 1192–1193
Craniomandibular osteopathy, in puppies
and kittens, 874
Crash cart, for cardiopulmonary
resuscitation, 959, 960–961
Cross bite, anterior, 887
posterior, 888
Crystallloid preparations, 615–617
Crystalluria, drug-associated, 261–265
Crystals, definition of, 18–19, 20
Ctenocephalides felis, 1407
Ctenocephalides species, hypersensitivity to,
1396–1397
clinical signs of, 1397–1398
diagnosis of, 1398
treatment of, 1398
Culicidae, allergic reactions to, 1393
Cutaneous asthenia, 910–911
Cyclooxygenase, role of, in homeostasis, 720–721
  in inflammation, 721–722
Cyclooxygenase–1, 722–725
Cyclooxygenase–2, 722–725
Cyclooxygenase–2 inhibitors, disadvantages of, 725
Cyclosporine, 1451
Cystine nephroliths, canine, 234
Cystine urolithiasis, canine, 193–211
  amino aciduria and, 197–198, 199–201
  biological behavior of uroliths in, 198–199
  diagnosis of, 199–202
  etiopathogenesis of, 196–198
  location of, 196
  medical dissolution of uroliths in, 202–209
  mineral composition and architecture of uroliths in, 195, 196, 197
  nonsurgical removal of uroliths in, 209
  prevalence of, 193–195
  prevention of, 209
Cystocentesis, decompressive, for canine retrograde urohydropropulsion, 268–270
Cystography, double contrast, in canine urocytoliths, 68–69
Cystourethroscopy, anesthetic management for, 680
Cytochrome P450 enzymes, drugs inducing or inhibiting, 632–633
Cytokine secretion patterns and intestinal T-cell functions, 475–477
Cytoprotective drugs, 360–362

D-Xylose absorption test, 448–449
Deafness, behavioral indicators of, 902
client counseling issues in, 905–906
conduction, 896
congenital, and its recognition, 895–907
  breeds of dogs with, 898
congenital acquired sensorineural, 896
congenital hereditary sensorineural, 897–901
electrodiagnosis of, 902–905
  genetics of, 901–902
  pathophysiology of, 896–901
Deconjugated bile acids, assessment of, to diagnose intestinal bacterial overgrowth, 541–542
Demineralized bone matrix, 1213
Demodectic mange, 911–912
Demodicosis, canine, 911–912
  adult-onset, 1426
  amitraz in, 1426–1427
  extra-label protocols for, 1427–1428
  classification of, 1425–1426
  prognosis in, 1434
  treatment of, considerations in, 1432–1433
  new approaches to, 1425–1436
Dental diseases, in kittens, 871–893
  in puppies, 871–893
L-Deprenyl, 1457–1458
Dermatitis, allergic inhalant, 910
  and otitis, Malassezia, 1303–1310
  facial and nasal, in feline herpesvirus 1, 1281–1290
  mycobacterial, 1291–1301
  perivulvar, following early spay-neuter, 940
  sterile nodular, in dogs, 1311–1323
  superficial necrotic. See Metabolic epidermal necrosis.
Dermatology, 1281–1473
  and World Wide Web, 1461–1473
human, sites of interest on World Wide Web and, 1466
pediatric, 909–920
  veterinary, new drugs in, 1449–1460
  sites of interest on World Wide Web and, 1467
Dermatomyositis, 912–913
juvenile, 1330
Dermatophytosis, 913–914
Dermatosis, zinc-responsive, in dogs, 1373–1383
Dermatosparaxis, 910–911
Descemetocoele, 1012–1013
Desflurane, and sevoflurane, 793–810
  as volatile anesthetic agent, 793–794
  cardiovascular effects of, 796–797
  central nervous system effects of, 798
  clinical experience with, in man, 802–803
  for geriatric patient, 696
  future veterinary use of, 805–806
  interaction with other agents, 800
  methods of administration of, 800–802
  pharmacological studies of, in large animals, 805
  in small animals, 803–804
  physical properties of, 795
  potency, and pharmacodynamics of, 794–796
  respiratory effects of, 797–798
  toxicity, metabolism, and stability with soda lime, 798–800
  vaporizer for administration of, 649
Dextran, 620–621
Diabetes mellitus, juvenile onset, 997
Diabetic dermatosis, canine, 1338
Diagnostic techniques, newer, impact of, on anesthesia, 665–682
Diaphragmatic hernia, congenital, in young cats, 954–955
Diarrhea, drug therapy of, 362
Dietary antigen, food allergy as response to, 491
Dietary sensitivity, colonic transport and, 582–585
Diet(s), as factor in development of urate uroliths, 166–167
for management of metabolic epidermal necrosis, 1351
for management of struvite uroliths, 90–91
for management of urate uroliths in mature dogs, 189–190
low-purine alkalinizing, in urate uroliths in immature dogs, 190–191
modification of, in calcium oxalate urolithiasis, 132–134, 135
in cystine uroliths, 204
in sterile struvite uroliths, 94
role of, in canine calcium oxalate uroliths, 115–118
Difloxacin, 1452
Digestion, by small intestine, tests of, 447–453
Distocclusion, 889
Distraction osteogenesis. See Osteogenesis, distraction.
Dobutamine, 825
Dogs, and cats, diagnostic imaging of gastrointestinal tract of, 307–342
nephrolithiasis in, 231–250
atopy in, advances in diagnosis and treatment of, 1437–1447
breeds with congenital deafness, 898
claw disease in, diagnosis and management of, 1357–1371
cutaneous tuberculosis in, 1299–1300
defarness prevalence in, breed-specific, 899, 900
eosinophilic furunculosis of face in, 1400–1402
gastric Helicobacter infection in, 397–414
eysoinoid granuloma syndrome in, 1298
metabolic epidermal necrosis in, 1338–1339
sterile nodular dermatitis in, 1311–1323
urolithiasis in. See Urolithiasis, canine.
zinc-responsive dermatosis in, 1373–1383
Dopamine, 825
Doxacurium, 814
Drug(s). See also specific drugs.
sorption of, in drug interactions, 631
affecting intestinal tract, 362–367
cytoprotective, 360–362
distribution of, in drug interactions, 631–632
for cardiopulmonary resuscitation, 960–961
for infection diseases, 1452–1455
for treating atopy, 1449–1451
for treatment of cardiac arrest, 825–827
gastric antisecretory, 356–360
hormonally related, 1456–1458
immunomodulator, 1455–1456
inducing or inhibiting cytochrome P450 enzymes, 632–633
interactions of, during anesthesia, 629–643
mechanisms of, 630–637
pharmaceutical, 630
pharmacodynamic, 634
pharmacokinetic, 630–634
metabolism and elimination of, in drug interactions, 632–634
new, in veterinary dermatology, 1449–1460
preanesthetic, 689–693
Duodenal/proximal jejunal bacteria, of cat, 524, 528
of dog, 524, 525–527
Dynamic compression plating, 1124, 1125, 1126, 1127
Dysplasia, hip. See Hip dysplasia.

Ehlers-Danlos syndrome, 910–911
Electrical cord injury, in puppies and kittens between 6 and 12 weeks of age, 976–977
Electrocardiographic rhythm, maintenance of, in cardiopulmonary resuscitation, 963–964
Electrohydraulic shock-wave lithotripsy, 293–302
Electrolyte transport, and colonic fluid transport, in health and disease, 577–588
Emetic reflex, sites that mediate, 347
Emetics, 343
centrally acting, 349
peripherally acting or reflex, 348–349
Enamel hypocalcification/hypoplasia, in puppies and kittens, 876–877
Endectocides, systemic macrocylic lactone, in canine demodicosis, 1429–1432
Endocrine disorders, failure to grow in, 994–997
Endocrine system, aging and, 687
effects of etomidate on, 781–782
Endodontic disease, 882–885
Endoscopy, 674–680
of upper and lower gastrointestinal tract, 674–676
Endotracheal tubes, 660–661
lasers and, 667
Enemas, 372
Enflurane, physical properties of, 795
Enrofloxacin, 1452
Enrofloxacin (Continued)
in canine parvovirus type 2 enteritis, 980–981
Enteric reflexes, organization of, 582
Enterocolitis, eosinophilic, 509
lymphocytic-plasmacytic, 508–509
Enteropathy(ies), antibiotic-responsive, 536–537
  gluten-sensitive, 488
  protein-losing, tests for, 459–460
Environmental flea control, 1418–1419
Eosinophilic enterocolitis, 509
Eosinophilic furunculosis, of face, canine, 1400–1402
Eosinophilic granuloma, canine, 1318–1319
clinical signs of, 1318–1319
diagnosis of, 1317–1318
treatment of, 1319
Epibatidine, 732
Epidermal growth factor, 1228
Epinephrine, in cardiac arrest, 825–826
Equipment, for inhalant anesthesia, 645–663
Erythromycin, in gastric motility disorders, 390–391
Etomidate, and Telazol, 779–792
  clinical uses of, 782–784
  composition of, 779
  contraindications to, 784–785
  effects of, on cardiovascular system, 780–781
  on central nervous system, 780
  on endocrine system, 781–782
  on respiratory system, 781
for geriatric patient, 695
limitations of, 784
precautions in use of, 785
side effects of, 784
suggested uses of, 789
Exocrine pancreatic disorders, feline, 551–574
Exophthalmos, following orbital abscess, 1006
External coaptation, 1076, 1083–1095
  application of, case presentation of, 1090–1093
  bandage materials and components for, 1089–1090
  cast materials for, 1090
  complications of, 1093–1094
  for fracture management, choosing of, 1084–1085, 1087, 1088
  principles of, 1083–1084
  fracture assessment for, 1084
  indications for, 1085, 1086–1088
  patient assessment for, 1083–1084
Extracorporeal shock-wave lithotripsy, 293–302
Eye(s), anterior segment of, emergency conditions in, 1009–1017
  posterior segment of, emergency conditions in, 1017–1018
  Eyelid(s), in ocular emergencies, 1007–1009
  lacerations of, 1008
  swollen–1009, 1008
  Face, dermatitis of, in feline herpesvirus 1, 1281–1290
eosinophilic furunculosis of, in dogs, 1400–1402
Fading kitten syndrome, 974
and neonatal isoerythrolysis, 853–870
Failure to grow, 989–1001
clinical signs of, and associated diseases, 991
diagnostic plan in, 990
disorders causing, 994–1000
and diagnosis of these disorders, 992–993
factors contributing to, 989
pathophysiological mechanisms of subnormal growth in, 990–994
Fat excretion, fecal, assaying of, 449
Fat tolerance test, oral, 449
Fatty acids, short-chain, assessment of, to diagnose intestinal bacterial overgrowth, 542
Fatty liver syndrome, in puppies and kittens between 2 and 6 weeks of age, 976
Feces, impacted, in cat, removal of, 595
Feeding, of kitten, 841–842
  of puppies, 839–840
  large and giant-breed, 841
Femur, biological osteosynthesis of, 1178–1179, 1180
  buttress plating and intramedullary pinning of, 1129
  interlocking nail fixation of, 1111, 1114
  intramedullary pinning of, 1100, 1101
Fenoxycarb, 1417
Fentanyl, 729
Fibrillation control, in cardiopulmonary resuscitation, 964
Fibroblast growth factor, functions of, 1227–1228
Fibula, biological osteosynthesis of, 1176–1177
Fipronil, for flea and tick control, 1410–1412
Flea(s), cat, 1407
  vaccine against, 1417
Flea control, advances in, 1407–1424
  environmental, 1418–1419
goals of, 1407
  indoor, 1418–1419
  insect resistance to, 1419–1420
  outdoor, 1418–1419
Fleas, 914–915
Flowmeters, on anesthesia machines, 646–647
Fluid and electrolyte composition of body, 612
Fluid balance, anesthesia and, 611 maintenance of, in perioperative period, 612
Fluid therapy, and newer blood products, 611–628
in canine parvovirus type 2 enteritis, 978–980
in cardiopulmonary resuscitation, 964 plan for, to improve tissue perfusion, 626
to replenish extracellular space, 626–627
Fluids, and disease, 625–626
and hemodynamic control, 624–626 hypertonic, 617
hypotonic, 617 indications for, 614–615 isotonic, 615–617
Flunixin, 727
Flunixin megamine, in canine parvovirus type 2 enteritis, 982–983
Fluoroquinolones, 1452–1453
induction of urolithiasis by, 255
Fluoxetine, 1451
Folate, concentrations of, tests of, to diagnose intestinal bacterial overgrowth, 542–543
serum concentrations of, assaying of, 449–453
Food allergy, as immune response to dietary antigen, 491
Foreign body(ies), chewing on, by puppies and kittens, 875
ingestion of, by puppies and kittens between 6 and 12 weeks of age, 976
ocular, 1013
Formicids, stinging by, 1389
Fracture(s), articulating nonunion of, 1247 biomechanics of bone and, 1045–1082 bone plates in, 1077
bones and, biomechanics of, 1045–1082 casts and splints to stabilize, 1076 circular external skeletal fixation of, 1078–1079
delayed union of, 1247, 1253, 1254
distracted nonunion of, 1254, 1256 fibrous nonunion of, 1247
fixation of, biomechanics of, 1073–1079 techniques of, and ability to neutralize disruptive forces, 1075
with screws and bone plates, 1117–1133 equipment for, 1117
healing of, endogenous growth factors in, 1222–1237
stages of, 1249
growth factors and, 1222–1227 infected nonunion of, 1254–1256 interlocking nail to neutralize forces on, 1077–1078
internal fixation of, 1097–1116 intramedullary pins in, 1076–1077 linear external skeletal fixation of, 1078
malunion of, 1252–1253
management of, and bone healing, 1029–1274 external coaptation for, principles of, 1083–1084
nonunion of, 1247, 1253–1254, 1255 causes of, 1041
patterns of, and bone loading, 1060–1061, 1062 postoperative disruptive forces on, 1074–1076 radiographic interpretation of, and radiology report, 1247–1249
repair of, failure of, 1041
radiography of, 1247–1260 treatment of, biological, with biological osteosynthesis, 1173–1174 mechanical, with biological osteosynthesis, 1171–1173
with circular external skeletal fixation, 1153–1170
union of, patterns of, 1039
wires and bone screws to maintain, 1079
Furunculosis, eosinophilic, of face, canine, 1400–1402
Gamma scintigraphy, anesthetic protocols for, 672–673
Gastric acid secretion, physiology of, 353–354
Gastric antisecretory drugs, 356–360
Gastric emptying, accelerated, 381 delayed, due to functional obstruction, 384–386
due to mechanical obstruction, 381–384
regulation of, 379–380
Gastric emptying rate, contrast radiography in assessment of, 311–314, 315
Gastric motility, disorders of, diagnosis and treatment of, 377–395 endoscopy and exploratory laparotomy in, 379
history and physical examination in, 377–378
laboratory findings in, 378
treatment of, 382, 386–391
types of, 380–386
tests to evaluate, 378–379
Gastric neoplasia, 415–440
endoscopic findings in, 426–431
epidemiology of, 416–417
etiology of, 415–416
exploratory laparotomy in, 432
hematological and biochemical findings in, 423–424
history and clinical signs of, 421–422
pathology of, 417–421
physical findings in, 422–423
prognosis in, 437
radiographic findings in, 424–426
staging of, 432–433
treatment of, 433–437
ultrasonographic findings in, 431–432
Gastroduodenal ulceration, pathophysiology of, 353
Gastrointestinal adsorbents, 367–369
Gastrointestinal diseases, 997–998
Gastrointestinal disorders, 307–603
doses of drugs used to treat, 344–346
Gastrointestinal immune-mediated disease, immune responses and, 492–493
Gastrointestinal immune response, regulation of, antigen presentation and, 479–481
Gastrointestinal immune system, normal function in, 477–483
Gastrointestinal immunity. See Immunity, gastrointestinal.
Gastrointestinal mucosa, defenses of, 354–355
Gastrointestinal pharmacology, 343–376
Gastrointestinal protectants, 367–369
Gastrointestinal tract, biopsy of, ultrasound-guided, 336–338
contrast radiography of, recent developments in, 311–314, 315
endoscopy of, 674–676
hypersensitivity reactions and immunopathology in, 488–491
microbes and, interactions between, in health, 529–530
of cat and dog, diagnostic imaging of, 307–342
of dog, lymphatic drainage of, 336
protective immune responses in, 483–486
radiography of, recent developments in, 309–311
secretions of, collection and culture of, 538–539
ultrasonography of, recent developments in, 315–338
Gastrointestinal ulceration, pathophysiology of, 353–355
Gender, effects of, on pharmacokinetics of propofol, 750–751
Geriatric patients, management of, 683–699
Giant Schnauzers, squamous cell carcinoma of claw bed in, 1358–1359
Glaucoma, acute, 1015–1016
Glucagonoma-like syndrome, and metabolic epidermal necrosis, in dog, 1342–1343
Glucagonoma syndrome, 1340–1342
in man, 1337–1338, 1340–1341
Glucocorticoids, 351
Gluten-sensitive enteropathy, 488
Gonadectomy. See Spay-neuter, early.
Greyhound, cutaneous and renal glomerular vasculopathy of, 1331
Growth, failure of. See Failure to grow.
stunted, following early spay-neuter, 940
Growth factor(s), affecting bone, potential uses for, 1238
B₂, transforming, 1215
bone-and nonbone-derived, and effects on bone healing, 1221–1246
clinical use of, considerations in, 1237–1238
endogenous, in fracture healing, 1222–1237
epidermal, 1228
fibroblast, 1227–1228
functions of, 1221–1222
influencing bone healing, 1039–1040
insulin-like, 1216, 1233–1237
platelet-derived, functions of, 1227
release of, 1224
synthesis of, 1227
transforming, 1228–1229
Growth hormone, 1216
Growth hormone deficiency, 994–995
H₂-Receptor antagonists, 356–358
Halothane, for geriatric patient, 696
interactions with carbon dioxide absorbent, 798–799
physical properties of, 795
Halothane hepatitis, 798–799
Haversian systems of, bone, 1034–1035, 1036
Health care, and management, pediatric, 837–852
kitten, 839
puppy, 837–839
Helicobacter infection, gastric, in dogs, 397–414
Helicobacter species, gastric, in dogs, characteristics of, 398
gastric function and, 401–402
inflammation caused by, 401
invasive diagnostic tests for, 402–405
noninvasive diagnostic tests for, 405–408, 409
pathogenicity of, 401
prevalence and transmission of, 398–400
public health implications of, 400–401
treatment of, 408–410
vaccination against, 410
Helminths, and immune responses in gastrointestinal tract, 485–486
Hemodynamic control, fluids and, 624–626
Hemorrhage, subconjunctival, 1009
Hepatic disorders, poor growth in, 999
Hepatitis, halothane, 798–799
Hepatocutaneous syndrome. See also Metabolic epidermal necrosis.
and metabolic epidermal necrosis, 1344–1349
pseudoglucagonoma syndrome and, 1342–1343
Hepatodermal syndrome. See Metabolic epidermal necrosis.
Herpesvirus, canine, 973–974
Herpesvirus 1, in domestic cats, clinical features of, 1282
diagnostic methods in, 1286
differential diagnosis of, 1285–1286
discussion of, 1287–1288
facial and nasal dermatitis and stomatitis associated with, 1281–1290
factors predisposing to, 1285
pathological lesions of, 1282–1284
therapy of, 1286–1287
Hetastarch, 619–620
Hip dysplasia, cause(s) of, environmental, 931–932
generic, 928–929
nutritional, 930–931
clinical diagnosis of, 922–926
recent information about, 921–934
treatment of, 926–928
Histiocytosis, cutaneous, clinical signs of, 1316–1317
diagnosis of, 1317–1318
treatment of, 1318
systemic, of Bernese Mountain Dog, 1319–1321
clinical signs of, 1320
diagnosis of, 1320–1321
therapy of, 1321
Hormonally related drugs, 1456–1458
Hormones, for regulation of insect molting, 1415–1417
House dust mite allergy, clinical signs of, 1399
diagnosis of, 1399–1400
immunopathogenesis of, 1399
treatment of, 1400
Humerus, buttress plating of, 1128
interlocking nail fixation of, 1113
intramedullary pinning of, 1101–1103, 1104
Humoral immunity, 481–482
Hyperadrenocorticism, 996
Hypercalciumia, normocalcemic, uroliths associated with, 148–149, 151
Hyperparathyroidism, 997
primary, uroliths associated with, 146–147
Hyperplasia, nodular, in cat, 568–569
Hypersensitivity reactions, and immunopathology, in gastrointestinal tract, 488–491
Hypersensitization protocol, modified, in dogs with atopy, 1444
Hypertonic fluids, 617
HypHEMA, 1015
Hypoadrenocorticism, 996
Hypoglycemia, juvenile, in puppies and kittens between 2 and 6 weeks of age, 975–976
Hyposomatotropism, congenital, 994–995
Hypothyroidism, 995
Hypotonic fluids, 617
Hypotrichosis, 915–916
Hypoxemia, pathophysiological causes of, 966
signs of, 966
Ilizarov method, 1153
general principles of, 1154–1161
Imaging, of skeleton, alternate methods for, 1258–1259
Imaging studies, anesthesia for, 668–674
IMEX SK system, 1139–1141
Imidacloprid, for flea control, 1412–1414
Imipenem-cilastin, 1453
Immune response(s), gastrointestinal, regulation of, antigen presentation and, 479–481
gastrointestinal immune-mediated disease and, 492–493
protective, in gastrointestinal tract, 483–486
Immune system, gastrointestinal, normal function in, 477–483
Immunity, gastrointestinal, and systemic responses, 492–493
in health and disease, 470–499
oral tolerance and, 482–483, 484
role of natural gut flora in, 486–488
humoral, 481–482
Immunodeficiency, 491
Immunomodulators, 1455–1456
for treating atopy, 1451
in inflammatory bowel disease, 515
Immunopathology, hypersensitivity reactions and, in gastrointestinal tract, 488–491
Immunotherapy, in canine parvovirus type 2 enteritis, 982
in dogs with atopy, 1442–1444
venom, in insect and arachnid hypersensitivity, 1391–1392
Impetigo, 917
Implants, biodegradable, 1130–1131
Indican, measurement of, to diagnose intestinal bacterial overgrowth, 541
Indirect reduction. See Osteosynthesis, biological.
Infection(s), bacterial, in kittens, 862
*Helicobacter*, gastric, in dogs, 397–414
in kittens, management of, 868
*Malassezia*. See Malassezia infections.
orthopedic, severe, bacterial isolates from, 1262
diagnosis of, 1262–1263
pathogenesis of, 1261
treatment of, 1261–1274
innovative, 1264–1270
traditional, 1263–1264
struvite uroliths induced by, biological behavior of, 86–87
management of, 89–94
viral, in kittens, 861–862
viral and bacterial, and immune responses in gastrointestinal tract, 483–485
Infectious diseases, drugs for treating, 1452–1455
in puppies and kittens between 6 and 12 weeks of age, 976–977
Inflammatory bowel disease, 488, 501–522
clinical syndromes of, 508–511
colonic, variants of, 509–510
dietary therapy in, 511–512
etiopathogenesis of, 502–504
extraintestinal manifestations of, 510–511
pharmacological therapy in, 512–515, 516
prognosis and response to therapy in, 517
relevant diagnostic testing in, 504–508
treatment of, 511–517
Inhalant allergy, to insects, 1400–1402
Insect(s), and arachnid allergens, 1385–1386
and arachnid hypersensitivity, 1385–1405
diagnosis and treatment of, 1389–1390, 1393–1394
diagnostic criteria in, 1387–1388
reactions to, delayed, 1387
immediate, 1386–1387
inhaled immediate, 1387
venom immunotherapy in, 1391–1392
biting, allergic reactions to, 1392–1393
diagnosis of, 1393–1394
treatment of, 1394
and stinging, hypersensitivity to, intradermal skin testing for, 1395–1396
growth of, regulation of, 1415–1417
inhalant allergy to, 1400–1402
resistance of, to insecticides, 1419–1420
stinging, and biting, hypersensitivity to, intradermal skin testing for, 1395–1396
systemic reactions to, 1390
diagnosis and treatment of, 1389–1390
venom immunotherapy in, 1391–1392
Insect allergens, 1385–1386
Insulin-like growth factors, 1216, 1233–1237
Intensive care, pediatric, 971–988
Interfragmentary strain theory, 1073
Interlocking nail fixation. See Nail fixation, interlocking.
Internet, 1461–1463
addresses, how to read and understand, 1464–1465
components of, 1461–1463
protocols used on, 1463
service providers, 1462
services of, 1462
Intestinal dilatation, quantitative analysis of, 309–311
Intestinal flora, of healthy cats and dogs, 523–529
Intestinal motility, tests of, 463–464
Intestinal parasites, eradication of, in canine parvovirus type 2 enteritis, 983
Intestinal parasitism, 845–846
Intestinal permeability, measurement of, in diagnosis of intestinal bacterial overgrowth, 543
Intestinal tract, drugs affecting, 362–367
physiology and pathophysiology of, 362–364
motility in, and secretions, modulators of, 364
ordered, 363–364
Intestinal transit, contrast radiography in assessment of, 311–314, 315
Intestine(s), small, bacterial activity in, tests of, 453–459
bacterial overgrowth in, 523–549
in dogs and cats, 534–536
in humans, 530–531
indirect diagnosis of, 539–543
pathophysiology of, 533–534
suspected, approach to patient having, 537–538
bacterial population in, factors influencing, 531–532
biopsy of, 464–466
digestion and absorption by, tests of, 447–453
function of, clinical laboratory evaluation of, 441–469
Juvenile
Isoerythrolysis, Ivermectin, Jack
Intramedullary Kitten(s), Kirschner-Ehmer
Kidneys, Ketorolac, Ketoprofen, Ketamine, Keratitis, Isoproterenol, Isotonic
Iridocyclitis, Ion
Isoflurane, neonatal
birth 6-
early feeding disease
dental infections congenital
diseases
diabetes mellitus
normal signs in, 971
sick, general approach to, 971-973
congenital abnormalities in, 856
dental diseases in, 871-893
early spay-neuter of, 847, 935-943
feeding of, 841-842
health care of, 839
infections in, management of, 868
malnutrition in, 846-847
neonatal disorders of, clinical presenta-
tion of, 854
diagnosis of, 863-865
etiology of, 854-862
infectious causes of, 860-862
management of, 865-868
noninfectious causes of, 854-860
nursing, milk replacer for, 843-844
oral cavity of, acquired lesions of, 875
developmental problems in, 871-874
pediatric health care program for, 851-
852
rearing of, 842-845
respiratory diseases in, 945-958
teeth of, development and formation of,
876-885
Lance tooth, 888
Laparoscopy, 676-677
Laryngoscopy, anesthesia for, 678
Laser surgery, accidents related to, 666-668
in veterinary medicine, 665-668
Laxative therapy, in cat, 595-598
Laxatives, 369
bulk-forming, 597
emollient, 369-370, 597
hyperosmotic, 598
lubricant, 597-598
simple bulk, 370
stimulant, 598
Leflunomide, 1456
Lens luxation, anterior, 1017
Leproid granuloma syndrome, canine, 1298
Leprosy, feline, 1298
Leukocytoclasia, 1325
Lidocaine, 826
Life support, postresuscitative, 964
Limb-sparing procedures, in orthopedic
infections, 1266-1267
Linear external skeletal fixation frame(s),
1136, 1137
Linear external skeletal fixators, in
fractures, 1078
Lipolized formulation, 1455
Lips, tight, in puppies and kittens, 873-874
Lithotomy, 1-3
Lithotripsy, shock-wave. See Shock-wave
lithotripsy.
Liver, aging and, 685
disease of, effects of, on pharmacokinet-
ics of propofol, 750-751
Loratadine, 1450
Lufenuron, in canine demodicosis, 1432
Lufenuron, for flea control, 1414-1415
Lungs, changes in, associated with aging,
684-685
contusions and lacerations of, in cats,
953
function of, effects of propofol on, 761-
763
neoplasia of, in cats, 954
Lymph nodes, abdominal, ultrasonography
of, 333-335
Macrocyclic lactone endectocides, systemic, in canine demodicosis, 1429–1432
Macrolide antibiotics, 1453–1454
Macrophages, as source of growth factors, 1224, 1225
Magnetic resonance imaging, challenges for anesthetist during, 670
general anesthesia for, 670
in bone trauma, 1259
monitoring during, 671–672
Malassezia dermatitis and otitis, 1303–1310
Malassezia infections, clinical presentation of, 1303–1306
diagnosis of, 1305–1306
therapy for, 1307–1308
zoonotic potential of, 1305–1306
Malnutrition, in puppies and kittens, 846–847
Macrocclusion(s), Class I (Neutoocclusion), 887–889
Class II (Mandibular brachygnathism, Overshot, Distocclusion), 889
Class III (Mesioclusion), 889
deciduous, 890–892
Mandibular brachygnathism, 889
Mange, demodectic, 911–912
otodectic, 916–917
Masks, face, for anesthesia delivery, 662
Maxillary canine rostroversion, 888
Medetomidine, 705–707, 741–742
Mediastinal diseases, in young cats, 956–957
Megacolon, idiopathic feline, diagnosis of, 591–594
dilated, surgery in, 599–600
history taking in, 591
hypertrophic, surgery in, 600
medical investigation in, 592–594
pathogenesis of, 589–591
diagnosis of, and therapy of, 589–603
physical examination in, 591–592
signalment of, 591
therapy of, 594–600
Melatonin, 1456–1457
Meloxicam, 727
Mesalamine preparations, in inflammatory bowel disease, 514
Mesentery, ultrasonography of, 331–333
Mesioclusion, 889
Metabolic disorders, failure to grow in, 997–1000
Metabolic epidermal necrosis, glucagonoma-like syndrome and, 1343
in cats, 1339
in dogs, 1338–1339
in man, 1337–1338
of Black Rhinoceros, clinical presentation of, 1339–1340
Metabolic epidermal necrosis-hepatocutaneous syndrome, 1337–1355
Metabolic epidural necrosis, and necrolytic migratory erythema, pathophysiology of, 1340–1343
clinical presentation of, 1343–1349
diagnosis of, 1349–1350
dietary protocol for management of, 1351
management of, 1350–1352
Metacarpal bones, intramedullary pinning of, 1103
Metatarsal bones, intramedullary pinning of, 1103, 1105
Methoprene, for flea control, 1416
Methoxyflurane, for geriatric patient, 695–696
Metoclopramide, 1351
in canine parvovirus type 2 enteritis, 981
in gastric motility disorders, 389–390
Metronidazole, in inflammatory bowel disease, 514–515
Microbes, and gastrointestinal tract, interactions between, in health, 529–530
Microglossia, in puppies and kittens, 873
Milbemycin oxime, in canine demodicosis, 1429–1430
Misoprostol, 1450
Mivacurium, 814
Monoamine oxidase inhibitors, drug interactions with, 634–635
Moxidectin, in canine demodicosis, 1432
Muscle relaxants, antagonism of, 815–816
Mycobacterial dermatitis, 1291–1301
antibiotic selection and treatment for, 1295–1298
history and diagnostic evaluation of, 1294–1295
Mycobacteriosis, atypical, 1291–1294
Nail fixation, interlocking, 1109–1115
complications of, 1115
nail insertion techniques using, 1111–1115
nails for, 1109–1110
to neutralize forces on fracture, 1077–1078
Narcotics, for geriatric patient, 691-692
Necrolytic migratory erythema. See also Metabolic epidermal necrosis.
and metabolic epidermal necrosis, pathophysiology of, 1340-1343
Neoplasia, gastric. See Gastric neoplasia.
pulmonary, in cats, 954
Nephroalcin, in calcium oxalate urolithiasis, 120-121
Nephroliths, medical dissolution of,
237-238
Nephrolithiasis, canine and feline, 231-250
biological behavior of nephroliths in,
234-235
clinical manifestations of, 235
diagnosis of, 235-237
frequency of occurrence of, 231-232
mineral composition and types of,
232-234
treatment of, 237-241
case report illustrating, 241-249
Neuroleptanalgesic combinations, for geriatric patient, 692-693
Neuromuscular blockade, monitoring of,
815
Neuromuscular blockers, newer, 811-817
doses of, in cats and dogs, 812
mechanism of action of, 812
Neutralization plating, 1125, 1127
Neurotrophic inclusion, 887-889
Neutrophilic leukocytoclastic vasculitis,
1325-1326
of Jack Russell Terrier, 1329-1330
Nitrous oxide, for geriatric patient, 697
physical properties of, 795
Nizatidine, in gastric motility disorders,
391
Nodular hyperplasia, in cat, 568-569
Nonsteroidal anti-inflammatory drugs,
analgesic actions of, 719, 720-728
mode of action of, 720-725
nitric oxide-releasing, 725
role in veterinary medicine, 728
Veterinary perioperative use of, 726-727
Nose, dermatitis of, in feline herpesvirus
1, 1281-1290
Nuclear medicine techniques, anesthetic
protocols for, 672-673
Nutritional support, in canine parvovirus
type 2 enteritis, 983

Onychomycosis, claw disease in,
1369-1370
Onychorrhexis, in claw disease, 1363
Opioids, 365-366, 719, 728-731
for geriatric patient, 691-692
Mu-, 728-730
partial and mixed agonist/antagonist,
730-731
Optic neuritis, 1017-1018
Oral cavity, acquired lesions of, in kittens
and puppies, 875
developmental problems of, in kittens
and puppies, 871-874
Oral tolerance, for management of
autoimmune disease, 492
gastrointestinal immunity and, 482-483,
484
Orbifloxacin, 1452
Orbit, treatment of, in ocular emergencies,
1003-1007
Organophosphates, in flea control, 1409
Orthopedic trauma, radiography of,
1247-1260
Osteoblasts, 1030, 1226
Osteoclasts, 1031-1032, 1033
Osteoconduction, 1208-1209
Osteocytes, 1031, 1032
Osteogenesis, 1208
distraction, 1187-1205
angular limb deformities and, 1199-
1202
biology of, 1189-1192
bone transport in, 1198-1199
circular external fixation and Ilizarov
method in, 1194-1202
circular external fixator components
for, 1189
clinical factors influencing, 1192-1194
complications associated with, 1203
consolidation in, 1194
corticotomy/osteotomy in, 1192-1193
distraction epiphysiolysis/chondrodi-
tasis in, 1195-1198
double-level lengthening in, 1194
fracture repair using, 1194-1195
frame stability influencing, 1192
historical perspectives on, 1187-1188
latency in, 1193
rate of distraction in, 1193
rhythm of distraction in, 1193-1194
veterinary applications of, 1188
veterinary circular external fixator sys-
tems for, 1188-1189
processes in, 1226
Osteogenic proteins, 1229-1231
Osteoglycin, 1231
Osteoinduction, 1208, 1226
Osteomyelitis, bone healing in presence of,
1256-1257
in limb-sparing procedures, 1266

Obesity, following early spay-neuter, 939
Occlusion, assessment of, 885-892
normal: Class O (orthocclusion), 886-887
Ocular emergencies, pediatric, 1003-1022
Onychodystrophy, in canine claw
disorders, 1359, 1363
Onychomadesis, in claw disease, 1363,
1369
Osteomyelitis (Continued)
posttraumatic, 1261–1262
Osteosynthesis, biological, 1130, 1171–1185
biological fracture treatment with,
1173–1174
 cancellous bone grafting in, 1182–1183
concept of balance in fracture
treatment with, 1174–1175
 less traumatic methods for application
of fixation hardware, 1179–1182
 less traumatic surgical approaches in,
1175–1177
 mechanical fracture treatment with,
1173–1174
 practicing progressive staged
 disassembly of fixation system in,
1183–1184
 rigid fixation systems in, to minimize
vascular insult to bone, 1177–1179
 shift of balance toward, strategies to
 apply for, 1175–1184
 bridging. See Osteosynthesis, biological.
Otitis, and dermatitis, Malassezia,
1303–1310
Otodectic mange, 916–917
Outpatient anesthesia, propofol for,
765–766
Ovariohysterectomy. See Spay-neuter, early.
Overshot, 889
Oxygen cage, 967
Oxygen supplementation, techniques for,
965–969
Oxygen therapy, cardiopulmonary
resuscitation and, 959–969
Pain, analgesics and, 701–717
and well-being, terminology associated
with, 702
 physiology of, 703–704
 recognition of, 702–703
 treatment of, 704–714
 versus distress, 702
Pancreas, ultrasonography of, 319–331, 332
Pancreatic abscess, in cat, 568
Pancreatic bladder, in cat, 568
Pancreatic disorders, feline exocrine,
551–574
Pancreatic insufficiency, exocrine,
diagnosis of, 448
 feline exocrine, clinical picture and diag-
nosis of, 562–563
 etiology and pathogenesis of, 561–562
 prognosis in, 565
 treatment of, 563–565
Pancreatic neoplasia, feline exocrine,
clinical signs and diagnosis of,
566–567
 etiology and pathogenesis of, 565–566
 prognosis in, 567
 therapy of, 567
Pancreatic parasites, in cat, 568
Pancreatic pseudocyst, in cat, 567
Panreatitis, feline, classification of, 552
 clinical picture and diagnosis of,
555–558
 etiology and pathogenesis of, 552–555
 mild, therapy of, 560–561
 prognosis in, 561
 severe, therapy of, 558–560
Pancuronium, 814
Panniculitis, sterile nodular, 1311–1314
 clinical signs of, 1312–1313
 diagnosis of, 1313–1314
 treatment of, 1314
Parasites, gastric, 385
 in puppies and kittens between 2 and 6
 weeks of age, 974–976
 intestinal, 945–946
 eradication of, in canine parvovirus
 type 2 enteritis, 983
 pancreatic, in cat, 568
 Parasitism, in kittens, 862
Parenteral solutions, composition of,
615–622
 Paronychia, bacterial, following claw tears,
1359, 1363
 in claw disease, 1363
 Parvovirus type 1, canine, 973–974
 Parvovirus type 2 enteritis, canine,
aggressive adjunctive treatments in,
982–983
 antiemetics in, 981–982
 drugs for management of, 978
 eradication of intestinal parasites in,
983
 immunotherapy in, 982
 initial assessment in, 977–978
 initial fluid therapy in, 978–979
 maintenance fluid therapy in, 979–980
 nutritional support in, 983
 protocol for optimal care in, 986–988
 systemic antibiotics in, 980–981
 Pectus excavatum, in young cats, 955–956
Pediatrics, 837–1022
 health care and management in, 837–852
Pentoxifylline, 1455–1456
 Periodinal disease, 881–882
 Perivulvar dermatitis, following early
spay-neuter, 940
 Pharmaceutical drug interactions, 630
Pharmacodynamic drug interactions, 634
Pharmacodynamics, age-related changes
in, 688
Pharmacokinetic drug interactions,
630–634
Pharmacokinetics, age-related changes in, 687–688, 751
Pharmacology, gastrointestinal, 343–376
Phenothiazines, 350
Phycomycosis, gastric, 383–384
Physical inspection, of puppy, 838
Pinnae, proliferative thrombovascular necrosis of, 1331–1332
Pins, alignment, 1181–1182
intramedullary. See Intra medullary pins.
transfixation, 1135–1136, 1144
Plaster of Paris implant, in orthopedic infections, 1269
Plate-pin construct, 1128–1130
Platelet-derived growth factor, functions of, 1227
release of, 1224
synthesis of, 1227
Pleural cavity, diseases of, in young cats, 954
Pleural effusion, in young cats, 955
Pneumocystography, in canine urocrystoliths, 67–68
Pneumonia, bacterial, in young cats, 951–952
Polyanhydrides, bioerodible, in orthopedic infections, 1269
Polyethylene spheres, barium-impregnated. See Barium-impregnated polyethylene spheres.
Polyglycolide, and polylactic polymers, in orthopedic infections, 1267, 1269
Poly lactic acid polymers, and polyglycolide, in orthopedic infections, 1267, 1269
in orthopedic infections, 1267–1269
Polymethyl methacrylate, antibiotic-impregnated, disadvantages of, 1267 in orthopedic infections, 1264–1266
Preanesthetic drugs, 689–693
Primidone, induction of urolithiasis by, 255
Procalamine, in canine parovirus type 2 enteritis, 983
Prokinetic agents, colonic, 598–599
Prokinetics, 352
gastrointestinal, mechanisms of, and sites of activity of, 388
Propofol, 747–778
alone, for induction and maintenance of anesthesia, 751–753
and inhalant anesthesia, 756–757
anesthetic properties of, 751–767
clinical use of, 765–767
effect of premedication on, 753–756
effects of, on cardiovascular function, 760–761
on cerebral physiology and brain wave activity, 763–764
on pulmonary function, 761–763
for cesarean section, 766–767
for geriatric patient, 694–695
for outpatient anesthesia, 765–766
intravenous administration of, blood concentration following, 750
distribution following, 749–750
metabolism and elimination following, 749
pharmacokinetics of, 748–749
effect of renal and hepatic disease, age, and gender on, 750–751
effects of other anesthetics on, 750
recovery from anesthesia with, 757–758
side effects of, 758–760
systemic effects of, 764–765
Proptosis, 1003–1006
Prostaglandin analogues, 359–360
for treating atopy, 1450–1451
Prostaglandin E2, 361
Prostaglandins, as mediators of inflammation, 1225–1226
α1-Protease inhibitor, fecal, to detect protein-losing enteropathy, 460
Proteins, bone morphogenic, 1215, 1229–1231
osteogenic, 1229–1231
Proton pump inhibitors, 358–359
Protozoa, and immune responses in gastrointestinal tract, 485
Protozoal parasites, in puppies and kittens between 2 and 6 weeks of age, 975
Pseudocyst, pancreatic, in cat, 567
Pseudoglucagonoma syndrome, and hepatocutaneous syndrome, 1342–1343
Pulmonary edema, in young cats, 952–953
Puppy(ies), 2- to 6-week old, sick, conditions causing, 974–976
6- to 12-week old, sick, conditions causing, 976–977
birth to 2-week-old, disease conditions of, 973–974
normal signs in, 971
sick, general approach to, 971–973
dental diseases in, 871–893
eye problems, 837–839
feeding of, 847, 935–943
health care of, 837–839
large and giant-breed, feeding of, 841
malnutrition in, 846–847
nursing, milk replacer for, 843–844
oral cavity of, acquired lesions of, 875
developmental problems in, 871–874
pediatric health care program for, 848–850
rearing of, 842–845
teeth of, development and formation of, 876–885
“Puppy pyoderma,” 917
“Puppy strangles,” 916, 977
Pyoderma, juvenile, 916, 977
“puppy,” 917
Pyogranuloma/granuloma syndrome, cutaneous sterile, 1314–1316
clinical signs of, 1314–1315
diagnosis of, 1315–1316
treatment of, 1316
Pyrethrins, for flea control, 1407–1408
synthetic, in flea control, 1408–1409
Pyrethroids, in flea control, 1408–1409
Pyriproxyfen, for flea control, 1416

Rabies vaccine, vasculitis induced by, with alopecia, 1330–1331
Radiographs, radiolucent spaces in bone in, 1257, 1258
Radiography, contrast, to assess gastric emptying rate, 311–314, 315
to assess intestinal transit, 311–314, 315
of gastrointestinal tract, recent developments in, 309–314, 315
of orthopedic trauma and fracture repair, 1247–1260
Radiopaque contrast agents, crystalluria associated with, 263–265
Radius, circular external fixation of, 1156, 1160, 1165
full cerclage wires and neutralization plating of, 1127
intramedullary pinning of, 1103
osteotomy of, 1234–1235
plate-pin construct of, 1129
Ranitidine, in gastric motility disorders, 391
Remifentanil, 729
Renal disease, poor growth in, 999–1000
Renal tubular acidosis, distal, uroliths associated with, 148, 151
Respiratory disease(s), feline, 945–958
therapeutic agents for management of, 947, 948
poor growth in, 999
Respiratory distress syndrome, acute, in young cats, 953
Respiratory system, congenital anomalies of, in cats, 945–946
effects of desflurane on, 797–798
effects of etomidate on, 781
effects of sevoflurane on, 797–798
effects of Telazol on, 786
Resuscitation, cardiopulmonary, new thoughts on, 819–829
cerebral, 827
Retina, detachment of, 1018
Retrograde transit, 381
Retrograde urohydropropulsion, canine. See Urohydropropulsion, canine retrograde.

Rhinoceros, 677–678
Ringworm, 913–914
Rocuronium, 814–815

Sacrum, cancellous bone screw for repair of, 1123
Scintigraphy, gamma, anesthetic protocols for, 672–673
to test intestinal motility, 463
Screws, and bone plates, fracture fixation with, 1117–1133
application of, 1122–1124
bone, and wires, to maintain fractures, 1079
length of, 1118
pitch of, 1118
self-tapping, 1118–1119
size of, 1118
Seborrhea, 917–918
Secur-U external fixation clamp, 1139, 1140
Sedatives, 704–705
for geriatric patient, 689–691
Septicemia, neonatal, 973
management in, 868, 985–986
Serotonin antagonists, 351–352
Serotonin reuptake inhibitors, drug interactions with, 636
Serotonin uptake inhibitors, for treating atopy, 1451
Sevoflurane, and desflurane, 793–810
as volatile anesthetic agent, 793–794
cardiovascular effects of, 796–797
central nervous system effects of, 798
clinical experience with, in man, 802, 803
for geriatric patient, 696
future veterinary use of, 805–806
interaction with other agents, 800
methods of administration of, 800–802
pharmacological studies of, in large animals, 805
in small animals, 803, 804–805
physical properties of, 795
potency, and pharmacokinetics of, 796
respiratory effects of, 797–798
toxicity, metabolism, and stability with soda lime, 798–800
vaporizer for administration of, 648–649
Shock-wave lithotripsy, electrohydraulic, 293, 294–298
and extracorporeal, 293–302
extracorporeal, 294, 298–300
and electrohydraulic, 293–302
for treatment of cats, 301
in treatment of bladder stones, 300–301
in treatment of ureteroliths, 300
Silica, inorganic, 213–214
organic, 214
Silica nephroliths, canine, 234
Silica urolithiasis, canine, 213–230
  biological behavior of uroliths in, 226
detection of, 226–227
epidemiology of, 214–215
etiopathogenesis of, 219–226
mineral composition and architecture of uroliths in, 215–219, 220, 221, 222
  recurrent, prevention of, 227–229
Silica uroliths, canine, medical management of, 227
induction of, sources of, 255
Skeletal fixation, circular external, advantages of, 1153–1154
and Ilizarov method, in distraction osteogenesis, 1194–1202
fracture treatment with, 1153–1170
  adjustability in, 1166
clinical results of, 1167
  complications of, 1167–1168,
  1201–1203
indications for, 1161
postoperative management in,
  1166–1167
preoperative planning for, 1164
surgical placement of frame for,
  1164–1166
history of, 1153
Ilizarov method of, 1153
  general principles of, 1154–1161
of fractures, 1078–1079
external, 1135–1152
linear external, of fractures, 1078
Skeletal fixation frame(s), linear external, 1136, 1137
Skeletal fixator systems, circular external, for distraction osteogenesis, 1188–1189
linear external, 1136–1141
Skeletal fixators, external, bone healing with, 1141–1142
linear external, classification and nomenclature of, 1135–1136
  complications with, 1149–1150
frame design of, 1142–1144
pin design of, 1144–1146
pin insertion technique for, 1146–1147
  principles of fracture management with, 1142–1148
soft tissue management and, 1147
staged disassembly of, 1147–1148
Skin testing, intradermal, for hypersensitivity to biting and stinging insects, 1395–1396
Snake teeth, 889
Sodium bicarbonate, 826–827
Solute distribution, body, 613
Somatotropin, 1232–1233
Somatotropin/insulin-like growth factor system, 1231–1237
Spay-neuter, early, adrenal disease and, 941
  anesthesia for, 936–937
  behavior and, 940–941
  lower urinary tract disease and, 938–939
  obesity and, 938–939
  of puppies and kittens, 847, 935–943
  pet overpopulation and, 937–938
  stunted growth/muscularity following, 940
surgical principles for, 937
techniques of, 936–937
urinary incontinence and perivulvar dermatitis following, 940
Spiral organisms, gastric, history of, 397–398
Splint(s). See also External coaptation.
  acrylic pin, 1138–1139
casts and, to stabilize fractures, 1076
Kirschner-Ehmer, 1136
Struvite, calcium, of claw bed, in Giant Schnauzers, 1358–1359
Sterile nodular dermatitis, in dogs, 1311–1323
Sterile nodular panniculitis. See Panniculitis, sterile nodular.
Stomach, ultrasonography of, 317–318, 320–321
Stomatitis, in feline herpesvirus 1, 1281–1290
Strabismus, following proptosis, 1005
Struvite nephroliths, canine, 233
Struvite urolithiasis, canine, and calcium oxalate urolithiasis, recurrence of, management of, 105
  biological behavior of, 86–88
  common characteristics of, 109–110
  current prevalence of, 74, 75
  etiopathogenic factors in, 75–86
  management of, precautions in patients with concomitant illnesses, 102–103
  medical dissolution of, 110–111
  and prevention of, 73–111
  recurrence of, minimizing of, 103–104
Struvite uroliths, canine, and calcium oxalate uroliths, changing prevalence of, 24–28
  infection-induced, treatment of, 3–4
  medical management of, current recommendations for, 88–103
  recurrence of, minimizing of, 103–104
  sterile, management of, 94–95
Subconjunctival hemorrhage, 1009
Succinylcholine, 813
Sucralfate, 361–362
Sufentanil, 729
Sulfasalazine, in inflammatory bowel disease, 513–514
Sulfonamides, crystalluria associated with, 261–263
induction of urolithiasis by, clinical relevance of, 253–255
epidemiology of, 253
risk factors for, 252–253
Superficial necrolytic dermatitis. See Metabolic epidermal necrosis.
Surgical techniques, newer, impact of, on anesthesia, 665–682

T-cell functions, intestinal, and cytokine secretion patterns, 475–477
Tabanidae species, allergic reactions to, 1392–1393
Telazol, adverse reactions to, 789
cardiovascular effects of, 785–786
clinical use of, 786–788
composition of, 785
contraindications to, 788–789
etomidate and, 779–792
general pharmacology of, 785
respiratory effect of, 786
side effects of, 788
suggested uses of, 789
Terbinafine, 1454–1455
Tetracycline, induction of urolithiasis by, 256
Thiol-containing drugs, in cystine urolithiasis, 204–208
Thoracic wall, diseases of, in young cats, 955–956
Thoracoscopy, anesthesia for, 679–680
Thrombovascular necrosis, proliferative, of pinnae, 1331–1332
Tibia, biological osteosynthesis of, 1176–1177
circular external fixation of, 1157, 1158, 1159, 1168
distraction osteogenesis of, 1196–1197
dynamic compression plating of, 1124
intramedullary pinning of, 1100–1101, 1102
screws and bone plates to reconstruct, 1120
Ticks, 918–919
Tight lip, in puppies and kittens, 873–874
Tolazoline, 742–743
Tooth(Teeth), abnormal structural formation of, 877
acquired lesions of, 881–885
development and formation of, in kittens and puppies, 876–885
eruption of, 878–880
position, abnormal, 887–889
Toxic milk syndrome, 974
Tracheobronchitis, infectious, in young cats, 949–951
Tracheobronchoscopy, anesthesia for, 678–679
Tramadol, 729–730
Tranquilization, analgesia versus, 702
Tranquilizers, 704–705
for geriatric patient, 689–691
Transfixation pins, 1135–1136, 1144
Transforming growth factor, 1228–1229
Transforming growth factor-B, 1215
Trauma, oral, to puppies and kittens, 875
Triatoma, allergic reactions to, 1394
Tricyclic antidepressants, and anesthesia, 635–636
drug interactions with, 635
Tuberculosis, cutaneous, in dogs and cats, 1299–1300
Tumors, in puppies and kittens, 874
Tylosin, 1453

Ulceration, gastroduodenal, pathophysiology of, 353
gastrointestinal, pathophysiology of, 353–355
Ulna, intramedullary pinning of, 1103
plate-pin construct of, 1129
Ultrasoundography, anesthesia for, 673–674
of abdominal lymph nodes, 333–335
of gastrointestinal tract, recent developments in, 315–338
of intestine, 318–319, 322–327
of mesentery, 331–333
of pancreas, 319–331, 332
of stomach, 317–318, 320–321
real-time, in canine urocrystoliths, 69–70
Ultrasound-guided biopsy, of gastrointestinal tract, 336–338
Urate urolithiasis, canine, 161–191
biological behavior of, 169–170
diagnosis of, 167–169
etiopathogenesis and risk factors for, 162–167
terminology associated with, 184–187
Urate uroliths, ammonium acid, canine, medical dissolution of, 188–189
medical dissolution of, 170–176
monitoring response to, 176–178
prophylactic therapy in, 178–179
surgical and medical combination therapy in, 176
Ureteroliths, extracorporeal shock-wave lithotripsy in, 300
Urethra, obstruction by urolith, effectiveness of voiding urohydropropulsion during, 285–286
Urethral catheterization, for temporary bypass of ureteroliths, 278–279
to dislodge ureteroliths, 279–281
Ureteroliths, lubrication of, for canine retrograde urohydropropulsion, 270
palpation of, for canine retrograde urohydropropulsion, 271
urethral catheterization for temporary bypass of, 278–279
urethral catheterization to dislodge, 279–281
Urinalysis, in cystine urolithiasis, 196, 199, 200, 201
Urinary incontinence, following early spay-neuter, 940
Urinary tract, lower, disease of, following early spay-neuter, 938–939
pain and trauma to, canine retrograde urohydropropulsion minimizing, 277–278
Urine, alkalinization of, in cystine urolithiasis, 208–209
Urocystoliths, canine, architectural characteristics of, 61–67
breed predisposition for, 60–61
detection of, techniques of, 67–70
epidemiological background of, 60–61
gender and age incidence of, 61
imaging of, 59–72
integrated approach to, 70–71
size, passing through urethra, determination of, 283–284
Urohydropropulsion, canine retrograde, decompressive cystocentesis for, 268–270
failure of, causes of, 269
lubrication of urethroliths for, 270
major steps for, 267–268
minimizing pain and trauma to urinary tract, 277–278
palpation of urethroliths for, 271
technique of, 271–277
verification and localization for, 268
voiding, 283–291
and urolith removal surgery, time between, 290
anesthesia for, 286
complications associated with, 289
effectiveness of, during obstruction of urethra by urolith, 285–286
urine in bladder lumen to enhance, 284–285
in large dogs, 286
in male dogs, 286
in recurrent urolithiasis, 290
learning to perform, 290
medical shrinking of urolith prior to, 286–287
uroliths lodged in urethra during, management of, 287–289
Urolithiasis, canine, 1–302
calcium oxalate. See Calcium oxalate urolithiasis, canine.
struvite. See Struvite canine urolithiasis.
definition of, 17
drug-induced, 251–266
recurrent, voiding urohydropropulsion in, 290
risk and protective factors for, 39–43
identification of, 40
interpretation for patient care, 40–42
reasons for, 40
study of, future directions in, 52
Urolith(s), allopurinol-induced xanthine. See Xanthine uroliths, allopurinol-induced.
calcium oxalate canine. See Calcium oxalate uroliths, canine.
canine, analysis of 77,000, 17–38
epilogue concerning, 16
formation of, 45–49
assessment of, 49–52
gross anatomical components of, 21–22
history of management of, 2–3
medical dissolution and prevention of, 1–16
mineral composition of, 20–21, 22
importance of, 31–34
mineral types of, in dogs less than 1 year of age, 28–31
quantitative analysis of, 22–24
paradigm shift created concerning, 12–13
seven steps from science to service in, 6–12
treatment of, case study of, 53–57
methods for evaluating, 45–57
definition of, 18–19, 20
drug-induced, prevalence of, 251–252
lodged in urethra, during voiding urohydropropulsion, management of, 287–289
medical shrinking of, prior to voiding urohydropropulsion, 286–287
naming of, 19
obstruction of urethra by, effectiveness of
voiding urohydropropulsion during, 285–286
removal surgery, and voiding urohydropropulsion, time between, 290
struvite canine. See Struvite uroliths, canine.
Uveitis, anterior, acute, 1013–1015
following proptosis, 1005

Vaccinations, for kittens, 839
for puppies, 838
Vaccine, against fleas, 1417
Vaporizers, 647–650
for administration of desflurane and sevoflurane, 800–801
Vascularized grafts, 1213
Vasculitis, and vasculopathy, cutaneous, 1325-1335
  clinical aspects of, 1327-1330
diagnosis of, 1332
histology of, 1325-1326
immunology of, 1326-1327
neutrophilic leukocytoclastic, 1325-1326
rabies vaccine-induced, with alopecia, 1330-1331
therapy of, 1332-1334
Vasculopathy, clinical aspects of, 1330--1332
  cutaneous and renal glomerular, of Greyhound, 1331
histology of, 1326
Vasopressin, 825-826
Vecuronium, 814
Venon immunotherapy, in insect and arachnid hypersensitivity, 1391-1392
Ventilation, cardiopulmonary resuscitation and, 820-822
Ventilators, anesthesia, 657-659, 660, 661
Vest cardiopulmonary resuscitation, in cardiac massage, 823
Viral infections, in kittens, 861-862
Vitamin B₁₂, serum concentrations of, assaying of, 449-453
Vomiting syndrome, bilious, 381
Vomition reflex, 343

Water, distribution, body, 612
dynamic exchange of, 612-613
  exchange of, between interstitium and plasma, 614
White coat pigment gene, breeds of cats carrying, 899
Wires, and bone screws, to maintain fractures, 1079
cerclage. See Cerlage wires.
World Wide Web, 1463-1465
  browsers and, 1464, 1465
  browsers and search engines, 1468-1469
  browsing the web and, 1468
depth and quality of information on, 1467-1468
dermatology and, 1461-1473
  finding dermatology information on, 1468
  how to make home page on, 1470-1471
  human dermatology sites of interest on, 1466
  hypertext markup transfer protocol, 1464
  searches of, 1468-1470
  terminology of, 1471-1473
  uses in dermatology, 1465-1470
  veterinary dermatology sites of interest on, 1466
Wry bite, 890

Xanthine nephroliths, canine, 233
Xanthine uroliths, allopurinol-induced, 256-261
  age, gender, and breed associated with, 256-257
  diagnosis of, 258-260
  etiopathogenesis of, 258
  location of, 257
  mineral composition and architecture of, 257
  prevalence of, 256
  prevention and treatment of, 260-261
Xenografts, 1213
Xylazine hydrochloride, 739-741
Xylose/3-0-methyl-D-glucose test, 449

Yohimbine, 743

Zinc, dietary requirements of, in dogs, 1373-1374
Zinc-responsive dermatosis, 1374
canine, 1373-1383
  clinical syndromes of, 1375-1378
  diagnosis of, 1378-1379
  therapy of, 1379-1381
  species manifesting, 1374
Statement of Ownership, Management and Circulation
(Required by 39 USC 3685)

1. Publication Title: Veterinary Clinics of North America: Small Animal Practice
2. Publication No.: 11
3. Filing Date: 9/15/99

4. Issue Frequency: Jan, Mar, May, Jul, Sep, Nov

5. No. of Issues Published Annually: 6
6. Annual Subscription Price: $36.00

7. Complete Mailing Address of Known Office of Publication, (not printer): (Street, apt., city, state, and ZIP code)
W.B. Saunders Company, Harcourt Brace & Company
6277 Sea Harbor Drive, Orlando, FL 32887-4000, Orange County
Contact Person: Carol Brooks
Telephone: 315-218-9139

8. Complete Mailing Address of Headquarters or General Business Office of Publisher: (not printer)
W.B. Saunders Company, The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399

9. Publisher (Name and complete mailing address)
Harry Denz, W.B. Saunders Company, The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399

10. Editor (Name and complete mailing address)
John Van Anda, W.B. Saunders Company, The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399

11. Managing Editor (Name and complete mailing address)
Cory Wolfs, W.B. Saunders Company, The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399

12. Owner (For non-profit, give name and address)
If owned by a corporation, give name and address of all shareholders owning or holding 1 percent or more of total amount of stock.
If owned by a corporation, give the names and addresses of all shareholders owning or holding 1 percent or more of total amount of stock.
If owned by a corporation, give the names and addresses of all shareholders owning or holding 1 percent or more of total amount of stock.
If owned by a corporation, give the names and addresses of all shareholders owning or holding 1 percent or more of total amount of stock.

13. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Security, if any, check box

14. Issue Date for Circulation Data Below
May 1999

15. Extent and Nature of Circulation
a. Total Number of Copies (for prior year)
6767
6700

b. Paid and/or Requested (Paid/Requested Outside-County Mail Subscriptions Based on Form 394)
4499
4317

(Outside County Subscriptions Include Advertiser’s proof and exchange copies)

Circulation
(2) Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and other Non-USPS Paid Distribution
764
697

(3) Other Class Mail Through the USPS

(4) Other Class Mail Through the USPS

c. Total Paid and/or Requested (Sum of 1, 2, 3, and 4)
5283
5014

d. Free Distribution
(1) Outside-County as Based on Form 394
93
89

by mail (Express, complimentary, and other free)

(2) In-County as Based on Form 394

(3) Other Class Mail Through the USPS

e. Total Free Distribution (Outside-Mailing or other means)
93
89

f. Total Distribution (Sum of 15a. and 15b.)
5377
5100

g. Copies not Distributed
4410
1397

h. Total (Sum of 15a. and 15b.)
6787
6700

i. Percent Paid and/or Requested (15a. divided by 15b. times 100)
98.5
98.2

16. Publication of Statement of Ownership

17. Signature of Editor, Publisher, Business Manager, or Owner

Kathleen Lee, Vice-President of Professional Services Marketing

I certify that all information furnished on this form is true and complete. I understand that the space furnish false or misleading information on this form or that causes material or information required by this form may be subject to criminal sanctions including fines and imprisonment and/or civil sanctions including civil penalties.